drugset / Trial / NCT02875080

Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects

NCT02875080

Phase 1 Completed 18 enrolled Otsuka Pharmaceutical Co., Ltd.
Non-randomizedCrossoverOpen-labelTreatment

Summary

The ratios of the geometric means of the ODT formulation to those of the reference formulation (conventional tablet) for the bioavailability variables (Cmax, AUCt, and AUC∞ of brexpiprazole (OPC-34712)).

Timeline

Start
2016-09-27
Primary completion
2016-11-27
Completion
2016-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 4 mg Oral

Indications

No indication recorded.